Incyte Corporation

INCY

NASDAQ

Healthcare

Biotechnology

Wilmington, DE, US2,617 employeesincyte.com

$95.95

+1.65(1.75%)

Mkt Cap $19.1B

$55.17

$110.57

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Product (54.2%), JAKAFI (21.5%), Royalty (8.5%).

8-K

Incyte Corporation announced title changes for three executives effective March 25, 2026: Pablo J. Cagnoni to President, Incyte and Global Head of Research and Development, replacing William J. Meury as President; Steven H. Stein to Executive Vice President, Chief Medical Officer and Head of Late-stage Development; and Mohamed Issa to Executive Vice President and Head of U.S. Commercial. No changes to compensation arrangements; Matteo Trotta will leave following a transition period.

$19.1B

Market Cap

$5.2B

Revenue

$1.3B

Net Income

Employees2,617

Fundamentals

How The Business Makes Money

Revenue by Segment

Product54.2%($22.3B)

JAKAFI21.5%($8.8B)

Royalty8.5%($3.5B)

OPZELURA3.7%($1.5B)

JAKAVI Royalty Revenues3%($1.2B)

JAKAVI3%($1.2B)

Olumiant Royalty1%($416M)

OLUMIANT1%($416M)

Milestone And Contract Revenues1%($400M)

ICLUSIG0.9%($360M)

MINJUVIMONJUVI0.7%($301M)

Pemazyre0.6%($252M)

NIKTIMVO0.4%($152M)

ZYNYZ0.2%($71M)

TABRECTA Royalty Revenues0.2%($67M)

TABRECTA0.2%($67M)

Other Product Royalty Revenues0%($12M)

Revenue by Geography

US94.1%($12.6B)

Europe5.7%($760M)

Other Countries0.2%($29M)

Activity

What Changed Recently

Management Change

Mar 29, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 26,

Management Change

Mar 25, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 25,

Financial Results

Feb 9, 2026

Results of Operations and Financial Condition. On February 10, 2026, Incyte Corporation issued a press release announcing financial results for its fourth fisca

Other Event

Mar 5, 2026

Other Events. On February 27, 2026, the U.S. Food and Drug Administration (“FDA”) issued a Complete Response Letter (“CRL”) for the supplemental Biologics Licen

Peer Companies

Company	Price	Change	Market Cap	P/E
BIIBBiogen Inc.	$177.12	-3.63%	$26.0B	20.8
UTHRUnited Therapeutics Corpo...	$564.24	-1.06%	$24.7B	17.3
DGXQuest Diagnostics Incorpo...	$198.02	+0.17%	$22.0B	21.9
RPRXRoyalty Pharma plc	$48.57	+0.17%	$20.8B	25.6
ILMNIllumina, Inc.	$127.26	+0.50%	$19.5B	22.3
WSTWest Pharmaceutical Servi...	$255.29	+1.01%	$18.4B	35.4
WATWaters Corporation	$304.52	+1.54%	$18.1B	28.0
ZBHZimmer Biomet Holdings, I...	$90.72	-0.34%	$18.0B	24.6

Analyst View

Company Profile

CIK0000879169

ISINUS45337C1027

CUSIP45337C102

Phone302 498 6700

Address1801 Augustine Cut-Off, Wilmington, DE, 19803, US

SEC EDGAR